ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

NTP Staff Members In Bethesda Told They Must Move

December 16, 1983

Schweiker Approves Transfer Of NTP’s NNCI Contribution To NIESH In FY’83

July 31, 1981

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

November 16, 1979

In Brief: Senate approves $13.69 Billion for NIH, House To Act This Week; Amounts Are Close

September 19, 1997

Test Of HHS Secretary’s Remarks On cancer Mortality Rate Findings

November 22, 1996

Drug Discovery Group Announcement Issued

January 7, 1983